News room
SUSTAINABLE PROVISION OF GENERIC MEDICINES IN EUROPE
Sustainable Provision of Generic Medicines in Europe
Prof. Steven Simoens
EGA Chair ‘European policy towards generic medicines’
KU Leuven Department of Pharmaceuticals and Pharmacological Sciences
Sustainable Provision of Generic Medicines in Europe on Vimeo.
ONLY INCREASED FOCUS ON GENERIC AND BIOSIMILAR MEDICINES CAN MAKE EUROPEAN HEALTHCARE SUSTAINABLE
Athens, 13 June 2013 - Addressing delegates at the 19th EGA Annual Conference in Athens, Gudbjorg Edda Eggertsdottir stressed that generic and biosimilar medicines companies ensuring high-quality manufacturing jobs and know-how should remain in Europe; benefiting society and patients and increasing the competitiveness and innovative capacity of our strategic industry.
EGA PRESIDENT CALLS ON MEMBER STATES TO BOOST MARKET ACCESS FOR BIOSIMILARS IN THE EU
London, 25 April 2013 - “Safe and effective biosimilar monoclonal antibodies will arrive soon” announced EGA President Gudbjorg Edda Eggertsdottir in her opening address at the 11th EGA International Symposium on Biosimilars today in London.
Guiding Principles
The EGA welcomes the publication of the Guiding Principles Promoting Good Governance in the Pharmaceutical Sector
Events
24 April 2013 - 28 September 2014
Publications
-
EGA Biosimilars Handbook
EGA Biosimilars Handbook Purchase PDF
EGA Biosimilars Handbook Italian version Purchase PDF -
EGA Q&A on the revised EMA Bioequivalence Guideline
EGA Q&A on the revised EMA Bioequivalence Guideline, the EGA Contribution to the Promotion of Harmonised EU interpretation of the revised Bioequivalence Requirement
Download PDF -
Vision 2015
EGA Vision 2015, the Way forward for more Efficient Regulatory Environment for Generic and Biosimilar Medicines
Download PDF -
How to Increase Patient Access to Generic Medicines in European Healthcare Systems
How to Increase Patient Access to Generic Medicines in European Healthcare Systems
Download PDF
